We previously reported a randomized trial comparing Cyclosporin-A (CsA) and short-term methotrexate versus CsA alone for graft-versus-host disease (GvHD) prophylaxis in 71 patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) from a human leucocyte antigen-identical sibling for severe aplastic anaemia (SAA). We found a better survival in the group receiving the two-drug prophylaxis regimen with no significant difference in the probability of developing GvHD between the two groups. The present study details chimaeric analysis and its influence on survival and GvHD occurrence in 45 of the original 71 patients in whom serial samples were available. Analysis was carried out in a blinded prospective manner. Seventy-two per cent achieved complete donor chimaerism (DC), 11% stable mixed chimaerism (SMC) and 17% progressive mixed chimaerism (PMC). The overall 5-year survival probability was 82% (711%) with a significant survival advantage (P ¼ 0.0009) in DC or SMC compared to those with PMC. Chronic GvHD was more frequent in DC patients, whereas no patient with SMC developed chronic GvHD. Graft failure occurred in 50% of the PMC group. This study demonstrates the relevance of chimaerism analysis in patients receiving HSCT for SAA and confirms the occurrence of mixed chimaerism in a significant proportion of recipients.
Introduction
Major strides have been made in the treatment of severe aplastic anaemia (SAA) in the last 30 years. The application of immunosuppressive therapy (IS) or allogeneic sibling bone marrow transplantation (BMT) has resulted in a decrease in mortality from approximately 80% to less than 20%. 1, 2 The therapeutic choice between allogeneic BMT from an human leucocyte antigen (HLA)-identical donor and IS is often difficult and depends upon disease severity, availability of a fully HLA-matched sibling donor, and patient age. Bacigalupo et al. 3 have recently outlined a guide to the choice of therapy for SAA.
Allogeneic sibling BMT for SAA is an attempt to replace the abnormal or damaged haematopoietic stem cell compartment of the patient with normal haematopoietic stem cells from a healthy donor. If successful, this results in so-called donor chimaerism (DC) , that is, all haematopoietic elements in the recipient are of donor origin. Other possible outcomes following allogeneic BMT include the persistence of recipient cells, known as mixed haematopoietic chimaerism (MC), or the re-establishment of host haematopoiesis, namely autologous recovery. Careful analysis of haematopoietic tissue following transplantation will reveal which of the above has taken place. 1 Factors that are known to influence haematopoietic chimaerism following BMT for SAA include the cell dose infused, previous blood or platelet transfusion, type of conditioning and concurrent use of immunosuppression. 4 Unlike the outcome of BMT for acute and chronic leukaemia, the development of graft-versus-host disease (GvHD) in patients with SAA does not provide any graftversus-aplasia effect or enhance survival. The establishment of stable mixed chimaerism (SMC) following BMT for SAA may result in a decrease in the incidence of acute GvHD. 5, 6 Graft failure or graft rejection may occur following allogeneic sibling BMT for SAA. Although the incidence is declining in Europe and North America, the occurrence of graft failure carries a poor prognosis and its treatment remains problematic. 7 Previous studies indicated that patients with SAA given Cyclosporin-A (CsA) and short term methotrexate (Mtx) for GvHD prophylaxis had a better outcome when compared with patients treated with Mtx alone. [8] [9] [10] [11] [12] [13] The clinical outcome of a prospective randomized study addressing the issue of using CsA alone versus CsA and Mtx for GvHD prophylaxis by GITMO/ EMBT, has recently been published. 14 We present here a detailed analysis of haematopoietic chimaerism following allogeneic BMT for SAA in a subgroup of patients receiving CsA alone or CsA and Mtx as GvHD prophylaxis from the GITMO/EBMT Study (Appendix). The data on patient outcome have been updated until May 2006.
Patients and methods

Patients
Patients undergoing BMT from an HLA-matched sibling donor, after a conditioning regimen consisting of cyclophosphamide alone, and enroled into the randomized trial comparing CsA alone or CsA and Mtx as GvHD prophylaxis, 14 entered the study. They were aged from 5 to 36 years and the diagnosis of SAA had been made according to previously reported criteria. 15 Twenty-seven patients had received anti-lymphocyte globulin and CsA and four patients were treated with granulocyte colonystimulating factor before transplantation. Patients with Fanconi anaemia were excluded from the analysis. Written, informed consent from patients or their parents was obtained. Only those patients with at least three serial samples for chimaerism analysis post-BMT were included in this study. The aim of this study was to determine, in a blinded prospective manner, the incidence of mixed haematopoietic chimaerism following BMT and to study its influence on graft failure, and on the incidence of both acute and chronic GvHD. Forty-five of the original 71 patients reported by Locatelli et al. 14 are reported in this study.
Samples
Bone marrow aspirates (BM) or peripheral blood smears (PB) were obtained from donor and recipient pre-transplant from each of the participating centres to permit informative polymorphisms to be defined for assessment of chimaerism post-BMT. Pre-transplant material was provided from each centre in the form of stored haematological slides (stained and unstained), which were sent to the co-ordinating centre (Dublin A median of four analyses was performed on material from each patient post-BMT (range 3-15). Myeloid and platelet engraftment were defined as the first of 3 consecutive days with a neutrophil count greater than 0.5 Â 10 9 /l and unsupported platelet count greater than 50 Â 10 9 /l, respectively. Patients were considered assessable for engraftment if they survived at least 14 days after transplantation.
DNA preparation
Preparation of DNA for chimaerism analysis from peripheral blood, bone marrow or haematological slides was as described previously. [16] [17] [18] When a number of haematological slides of high cellularity were provided, material was scraped from slides directly into a digestion buffer containing Proteinase K and sodium dodecyl sulphate. Following digestion at 371C for 1-2 h, cellular debris was pelletted and DNA was extracted from the aqueous layer. Material from stained haematological slides was subsequently subjected to several rounds of phenol/phenol-chloroform extractions and DNA was extracted by ethanol precipitation. If limited material was available, polymerase chain reaction (PCR) was performed on material scraped from a section of the slide following incubation at 1001C for 20 min under oil to effect cell lysis and DNA liberation. DNA separation from PB and BM was performed using standard methods.
Polymerase chain reaction A panel of short tandem repeat (STR) primers was used to distinguish donor and recipient profiles pre-transplant, as reported previously. [16] [17] [18] At least two informative polymorphisms were used to screen post-transplant samples to ensure accurate assessment of chimaerism. Samples were amplified in 25 ml volumes with the incorporation of radioactive cytosine triphosphate ( 32 P dCTP), as described previously. 18 Following amplification, samples were electrophoresed on 6-8% polyacrylamide sequencing gels and results were analysed after exposing gels to autoradiography for 4-24 h. Visual analysis of autoradiographs allowed optimal scoring of donor, mixed or recipient profile post-BMT. Estimations of the percentage of donor and recipient cells in MC samples were subsequently performed by comparison with dilutions of donor and recipient cells. This allowed estimation of the percentage of recipient cells, with a sampling error of 75% for levels of recipient less cells 410%. The presence of recipient cells at less than 0.1% control were all scored as o1%. Comparison of serial samples allowed reliable determination of stable or progressive mixed chimaerism (PMC). Results were confirmed by amplification with a second informative marker. 
Definitions of chimaerism
Statistical analysis
Outcomes analysed were graft failure, defined as primary non-engraftment in patients surviving 421 days, or graft failure after initial engraftment, grade I-II acute GvHD (no higher grade acute GvHD was encountered), chronic GvHD of any grade, and overall survival. The w 2 or Fisher's exact test was used where appropriate to compare among groups the proportion of patients in different categories. Kaplan-Meier estimates (795% confidence intervals) were used to calculate survival. Cumulative incidence adjusting for competing risks, that is death from other causes, was used for graft failure and GvHD. Groups were compared using the log-rank test.
Results
Forty-five patients from 11 centres in Europe entered the study. Patient characteristics are reported in Table 1 . The overall rate of achieving DC was 72%; 49% of patients exhibited DC at all times post-transplant and 23% of patients exhibited TMC reverting from MC to DC within 6 months. SMC occurred in 11% (five patients) of recipients and eight patients (17%) showed an increasing number of host cells over time, that is PMC. The group receiving CsA showed 45% DC and the CsA þ Mtx group 56% DC (see also Table 2 ). There was a higher incidence of successful engraftment defined as DC þ TMC in patients receiving CsA þ Mtx (84%) compared to CsA alone (65%), but this difference did not reach statistical significance (P ¼ 0.1).
Ten patients died. Six of the deaths were in the CsA arm and four in the CsA þ Mtx arm. Causes of death included acute GvHD (one patient), chronic GvHD (one patient), viral infections (two patients), fungal infections (two patients), organ failure (two patients), donor leukaemia (one patient) and unknown (one patient). The overall survival at 5 years was 82 (711)% ( Figure 1a) ; it was 72 (720)% in the CsA arm and 92 (711)% in the CsA þ Mtx arm (Figure 1b) , the difference not being significant. Survival at 5 years differed considerably according to chimaerism status; patients with DC had a survival rate of 86 (716)%, TMC 91 (717)%, SMC 100% and PMC 38 (734)% (P ¼ 0.0009) (Figure 2) . Table 3 shows the cumulative incidence of acute and chronic GvHD and of graft failure in both study groups and in each chimaerism category. The incidence of chronic GvHD was slightly higher in the group receiving CsA þ Mtx compared to CsA alone but this did not reach statistical significance. Chimaerism status did not influence the degree of acute GVHD. In contrast, as shown in Figure 3 , chronic GvHD incidence was higher in TMC and DC chimaerism groups as compared to PMC and SMC (P ¼ 0.03). No patient with SMC developed chronic GvHD. The cumulative incidence of graft failure was 9% (3-22%). In the PMC group, cumulative incidence of graft failure was 50% (25-99)%. The numbers of patients with limited or extensive cGvHD were too few for meaningful analysis.
Discussion
Locatelli et al.
14 reported a randomized trial comparing CsA and short-term Mtx versus CsA for GvHD Aplastic anaemia BMT chimaerism graft-versus-host disease S McCann et al prophylaxis in 71 patients undergoing allogeneic BMT from an HLA compatible sibling. They found a better survival in the group receiving CsA and Mtx and no significant difference in the probability of GvHD, grade II, III or IV between the two groups. Forty-five of these patients who had a chimaerism analysis performed on at least three occasions were enroled in this study. As in the publication by Locatelli et al., 14 the demographic data were comparable in both prophylaxis groups in this study ( Table 1 ). The data were updated to May 2006. The groups were analysed for their chimaeric status and the influence of this on survival, GvHD and graft failure. In order to exclude bias between patients in whom chimaerism studies were, or were not carried out from the original group of 71, the overall survival of both groups was compared. There was no difference in survival between the two groups, the 5 year survival of those not included in the chimaerism analyses being 90% (79-100) 95% CI and those included 84% (73-96) 95% CI (P ¼ 0.74).
As the conditioning regimen commonly used for patients with SAA is non-myeloablative (cyclophosphamide 200 mg/kg recipient body weight), it was not surprising that MC was detected in at least one analysis on 51% of the recipients ( Table 2) by PCR of STRs, a finding similar to that reported by Huss et al., 6 in a nonrandomized study, using cytogenetics and fluorescence in situ hybridization. At last follow-up, 72% had achieved complete DC, 11% were SMC and 17% had PMC. In the PMC group, four patients lost their graft. The group receiving prophylaxis with CsA þ Mtx exhibited more DC (DC þ TMC) than the group receiving CsA alone but this did not reach statistical significance. Survival was marginally better in the group receiving CsA þ Mtx (84 versus 82%), whereas Locatelli et al.
14 found a significant difference in favour of CsA þ Mtx (P ¼ 0.05). This discrepancy may be due to the fact that only a subgroup of the original cohort was eligible for this study. Patients with PMC had a higher mortality than any of the other groups (Figure 3 ) because of the high incidence of graft failure, and patients with SMC had 100% survival and no GvHD. Huss et al. 6 also found a better survival in the MC group (64 versus 43%) but only in the patients receiving Mtx or CsA alone. They found no survival advantage and an increased GvHD rate in MC receiving CsA þ Mtx. This is difficult to understand as the evidence from our randomized study indicates that SMC is the ideal state following BMT for SAA with a low mortality rate (zero in this study).
Among the patients enroled into this study, only grade I-II acute GvHD was diagnosed. There was a trend towards more patients with acute GvHD in the DC and TMC category, but recipients with DC and TMC had significantly more chronic GvHD than patients in the SMC and PMC categories. Similarly, Hill et al. 19 reported a reduced incidence of GvHD in patients who were MC. In our randomized study, no patient with SMC developed chronic GvHD. Thus, we were unable to corroborate the findings of Huss et al. who found that MC following CsA þ Mtx was associated with more, and not less GvHD compared with either drug used alone as prophylaxis. They suggested that this might be due to a complex interaction between the combination of drugs, allogeneic signals and cytokines. However, the effect of SMC on chronic GvHD was beneficial in our study, as no patient in this group developed chronic GvHD irrespective of the prophylaxis.
Graft failure may occur in a significant number of patients following BMT for SAA. A number of recent studies indicate that the incidence of graft failure is decreasing. 7, 20, 21 Factors contributing to graft failure include: intensity of the conditioning regimen, number of stem cells infused, number of T cells infused, type of post-BMT immunosuppression and degree of HLA matching in the donor/recipient pair. 22 The pattern of haemopoietic chimaerism post-BMT also influences the possibility of graft failure. Using PCR of STRs, Lawler et al. 23 showed that PMC was associated with a high risk of graft failure (76%), a finding that Huss et al. 6 confirmed. Earlier studies had demonstrated a reduction in graft failure rates by incorporating total body irradiation or thoraco-abdominal irradiation into the conditioning regimens [24] [25] [26] but because of the subsequent finding of secondary tumours, 27 irradiation can no longer be recommended for BMT for SAA.
In this study, approximately 75% of patients became full DC following non-myeloablative conditioning, whereas the remaining patients were either SMC or experience PMC. SMC would appear to be ideal and seems to be associated with the best survival and the lowest risk of GvHD.
